Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance

INTRODUCTION: Despite significant clinical advancement with the use of immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) there are still a major subset of patients that develop adaptive/acquired resistance. Understanding resistance mechanisms to ICB is critical to developing new...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, B. Leticia, Chen, Limo, Li, Yanli, Miao, Shucheng, Peng, David H., Fradette, Jared J., Diao, Lixia, Konen, Jessica M., Alvarez, Frank R. Rojas, Solis, Luisa M., Yi, Xiaohui, Padhye, Aparna, Gibson, Laura A., Ochieng, Joshua K., Zhou, Xiaofei, Wang, Jing, Gibbons, Don L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336223/
https://www.ncbi.nlm.nih.gov/pubmed/37449205
http://dx.doi.org/10.3389/fimmu.2023.1161869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336223/
https://www.ncbi.nlm.nih.gov/pubmed/37449205
http://dx.doi.org/10.3389/fimmu.2023.1161869

Ejemplares similares